Novartis Shares Phase III GCAptAIN Trial Results for Cosentyx in Giant Cell Arteritis

Novartis announced top-line results from the Phase III GCAptAIN trial assessing Cosentyx (secukinumab) in patients with giant cell arteritis (GCA). The study compared Cosentyx with a 26-week steroid taper to placebo with a 52-week taper. Cosentyx did not show a statistically significant improvement in sustained remission at Week 52, though it demonstrated numerically better outcomes for steroid use and related toxicity. Safety results aligned with Cosentyx’s established profile.

The global trial involved over 27 countries and tested 300 mg and 150 mg Cosentyx doses. Novartis plans to fully evaluate and present the data later.

Cosentyx, an IL-17A inhibitor, is already approved for multiple immune-mediated conditions and has treated over 1.8 million patients worldwide. GCA, a serious vasculitis affecting those over 50, can lead to vision loss and aortic complications if untreated.

08-07-2025